In Reply We described the results of a phase 2 clinical trial demonstrating the safety, tolerability, and durable immunogenicity of a CHIKV VLP vaccine at 6 chikungunya-endemic sites in the Caribbean.1 Dr Jaiswal and colleagues highlight the favorable safety profile of the vaccine and inquire as to the reason for the study participant withdrawals described as “investigator or study decision” and requested the genotype-specific neutralization assay results.
Chen GL. Chikungunya Virus–Like Particle Vaccine—Reply. JAMA. 2020;324(10):1008–1009. doi:10.1001/jama.2020.11859
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: